New Drug Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
Larotrectinib Targets Rare Genetic Abnormality, TRK Fusions
FOR IMMEDIATE RELEASE
June 3, 2017
Summary includes updated data not in the abstract
ASCO Perspective
“Though the study is small and early, it demonstrates compelling evidence that may pave the way for a new class of drugs for rare tumors that could inform the future of precision medicine,” said Sumanta Kumar Pal, MD, ASCO Expert.
“Though the study is small and early, it demonstrates compelling evidence that may pave the way for a new class of drugs for rare tumors that could inform the future of precision medicine,” said Sumanta Kumar Pal, MD, ASCO Expert.
No hay comentarios:
Publicar un comentario